These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
372 related items for PubMed ID: 20082241
21. [The diagnostic evaluation and therapeutic basis of immediate release methylphenidate in attention deficit hyperactivity disorder]. Valdizán JR. Rev Neurol; ; 38(6):501-6. PubMed ID: 15054710 [Abstract] [Full Text] [Related]
22. Safe and effective methylphenidate therapy in a pediatric patient with glaucoma. Lewis H, Lewis J. Atten Defic Hyperact Disord; 2012 Mar; 4(1):37-9. PubMed ID: 22311620 [Abstract] [Full Text] [Related]
23. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Fallu A, Richard C, Prinzo R, Binder C. Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338 [Abstract] [Full Text] [Related]
24. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Findling RL. Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941 [Abstract] [Full Text] [Related]
25. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. Childress AC, Sallee FR, Berry SA. Postgrad Med; 2011 Sep; 123(5):80-8. PubMed ID: 21904089 [Abstract] [Full Text] [Related]
26. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate. Treceño C, Martín Arias LH, Sáinz M, Salado I, García Ortega P, Velasco V, Jimeno N, Escudero A, Velasco A, Carvajal A. Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):435-41. PubMed ID: 22253017 [Abstract] [Full Text] [Related]
27. Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder. Gormez V, Avery B, Mann H. Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2345-9. PubMed ID: 24065228 [Abstract] [Full Text] [Related]
28. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, Civil R. Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143 [Abstract] [Full Text] [Related]
29. Predictive factors for more than 3 years' duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: a retrospective, naturalistic study. Torgersen T, Gjervan B, Nordahl HM, Rasmussen K. J Clin Psychopharmacol; 2012 Oct; 32(5):645-52. PubMed ID: 22926598 [Abstract] [Full Text] [Related]
30. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM. Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216 [Abstract] [Full Text] [Related]
31. Efficacy of a methylphenidate transdermal system versus t.i.d. methylphenidate in a laboratory setting. Pelham WE, Waxmonsky JG, Schentag J, Ballow CH, Panahon CJ, Gnagy EM, Hoffman MT, Burrows-MacLean L, Meichenbaum DL, Forehand GL, Fabiano GA, Tresco KE, Lopez-Williams A, Coles EK, González MA. J Atten Disord; 2011 Jan; 15(1):28-35. PubMed ID: 20439487 [Abstract] [Full Text] [Related]
32. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Kim JH, Park MK, Park S, Park JH, Oh EY, Lim TS, Cheong S, Cho IH, Choi JW. Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan 30; 31(1):210-6. PubMed ID: 17046131 [Abstract] [Full Text] [Related]
33. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Prince JB. Child Adolesc Psychiatr Clin N Am; 2006 Jan 30; 15(1):13-50. PubMed ID: 16321724 [Abstract] [Full Text] [Related]
34. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study. Huang YS, Guilleminault C, Li HY, Yang CM, Wu YY, Chen NH. Sleep Med; 2007 Jan 30; 8(1):18-30. PubMed ID: 17157069 [Abstract] [Full Text] [Related]
35. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. Quinn D, Wigal S, Swanson J, Hirsch S, Ottolini Y, Dariani M, Roffman M, Zeldis J, Cooper T. J Am Acad Child Adolesc Psychiatry; 2004 Nov 30; 43(11):1422-9. PubMed ID: 15502602 [Abstract] [Full Text] [Related]
36. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, August G, Greenhill L, McBurnett K, Palumbo D, Swanson J, Wolraich M. J Am Acad Child Adolesc Psychiatry; 2003 Apr 30; 42(4):424-33. PubMed ID: 12649629 [Abstract] [Full Text] [Related]
37. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Konstenius M, Jayaram-Lindström N, Beck O, Franck J. Drug Alcohol Depend; 2010 Apr 01; 108(1-2):130-3. PubMed ID: 20015599 [Abstract] [Full Text] [Related]
38. Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children. Prescrire Int; 2004 Dec 01; 13(74):203-6. PubMed ID: 15612099 [Abstract] [Full Text] [Related]
39. A randomized, rater-blinded, crossover study comparing the clinical efficacy of Ritalin(®) LA (methylphenidate) treatment in children with attention-deficit hyperactivity disorder under different breakfast conditions over 2 weeks. Schulz E, Fleischhaker C, Hennighausen K, Heiser P, Haessler F, Linder M, Stollhoff K, Warnke A, Baier M, Klatt J. Atten Defic Hyperact Disord; 2010 Nov 01; 2(3):133-8. PubMed ID: 21432599 [Abstract] [Full Text] [Related]
40. Quillivant XR--an extended release oral suspension of methylphenidate. Med Lett Drugs Ther; 2013 Feb 04; 55(1409):10-1. PubMed ID: 23381227 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]